Navigation Links
Shire Reaches Agreement in Principle With U.S. Government

PHILADELPHIA, February 1, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to ADDERALL XR®, VYVANSE® and DAYTRANA®[1].  

The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009.  The agreement also addresses sales and marketing practices relating to LIALDA® and PENTASA® pursuant to a subsequent voluntary disclosure made by Shire.  

Shire cooperated with the U.S. Government throughout the process that led to this agreement in principle.  Shire has recorded a $57.5M charge in the fourth quarter of 2012, comprised of the agreement in principle amount, interest and costs.  

The agreement in principle is subject to change until this matter is finally resolved.  Discussions between Shire and the U.S. Government are ongoing to establish a final resolution to the investigation.

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.


1. DAYTRANA® is a trademark of Noven Pharmaceutical Inc.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations Eric Rojas +1-781-482-0999 Sarah Elton-Farr +44(0)1256-894157 Media Jessica Mann (Corporate) +44(0)1256-894-280

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
2. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
3. Shire Changes its NASDAQ Ticker Symbol to SHPG
4. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
5. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
6. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
9. Mold from Sandy Remains a Problem in Rockaways; My Cleaning Products Reaches Out to Help with Its Green Mold Removal Spray
10. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
11. Cold Adds Up to Sandy Victims' Mold Problems; Optimal Chemical Reaches Out to Help by Advising the Use of Molderizer
Post Your Comments:
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... into a non-binding Letter of Intent (LOI) with MediTemp Ltd. ... developed a proprietary cooling technology designed to improve sperm quality ... the United States and three million men in ... and 44 diagnosed as infertile.  For 42% of those men, ...
(Date:10/13/2015)... ... 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to ... data solutions business. , Jeff Parr has spent the past decade providing quality management ... Thermo Fisher, and Ab Sciex to name a few. He is based in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove ... to announce their partnership with the Keck Medicine of the University of ... , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and ...
Breaking Biology Technology:
(Date:10/8/2015)... , October 8, 2015 ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet announces that revenues for ... approximately $410,000 compared with $113,00 for the three ... 9 months ended September 30, 2015 were approximately ...
(Date:10/5/2015)... , October 5, 2015 ... company update for NXT-ID, Inc. (NASDAQ: NXTD ), ... commerce market. --> ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... SoundView Technology Group ( ) ...
(Date:9/30/2015)... Sept. 30, 2015  The global glucose monitoring device and ... So says a new report on the industry from Kalorama ... dominate the market, followed by continuous glucose monitoring and sensor ... the market for these products in its latest report, ... , ...
Breaking Biology News(10 mins):